Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Bin-Shyun Lee"'
Autor:
Ann-Lii Cheng, Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Muh-Hwa Yang, Chiun Hsu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly define
Externí odkaz:
https://doaj.org/article/e201d6a5e75748548d0e5d642dbb22fa
Autor:
Da-Liang Ou, Bin-Shyun Lee, Ya-Chi Chang, Liang-In Lin, Jun-Yang Liou, Chiun Hsu, Ann-Lii Cheng
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66589 (2013)
Insulin-like growth factor (IGF) signaling pathway is an important regulatory mechanism of tumorigenesis and drug resistance in many cancers. The present study explored the potential synergistic effects between IGF receptor (IGFR) inhibition and othe
Externí odkaz:
https://doaj.org/article/a4b938d77d50470cbe88c34900703138
Autor:
Lin Li, Chia-Lang Hsu, Liang-In Lin, Bin-Shyun Lee, Ping-Yun Ou, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou
Publikováno v:
Cancer Research. 83:376-376
As part of our previous studies on the anti-tumor mechanisms of sorafenib, one of the primary treatments for advanced hepatocellular carcinoma (HCC), we found that suppression of cyclin E1 in HCC cells correlates with sensitivity to sorafenib (Chiun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7973f45ac0f9f21f7c0c079118a62c9f
https://doi.org/10.1158/1538-7445.am2023-376
https://doi.org/10.1158/1538-7445.am2023-376
Autor:
Yu-Yun Shao, Pai-Sheng Chen, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou
Publikováno v:
Br J Cancer
BACKGROUND: Sorafenib is one of the standard first-line therapies for advanced hepatocellular carcinoma (HCC). Unfortunately, there are currently no appropriate biomarkers to predict the clinical efficacy of sorafenib in HCC patients. MicroRNAs (miRN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55deff32dcc5669f5e84dd498ff5cbe8
https://europepmc.org/articles/PMC9174288/
https://europepmc.org/articles/PMC9174288/
Publikováno v:
Annals of Oncology. 33:S483
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f736dd119e1797392a0be6242c335e45
https://doi.org/10.1016/j.annonc.2022.05.108
https://doi.org/10.1016/j.annonc.2022.05.108
Autor:
Da-Liang Ou, Chiun Hsu, Zi Rui Feng, Chih Hung Chung, Chia Wei Chen, Chia Lang Hsu, Muh Hwa Yang, Bin Shyun Lee, Ann-Lii Cheng
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundRegorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly defined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2430a9173a63e99c2faeea1f2934d573
https://pubmed.ncbi.nlm.nih.gov/33753566
https://pubmed.ncbi.nlm.nih.gov/33753566
Autor:
Da-Liang Ou, Chiun Hsu, Jun-Yang Liou, Hsiang-Hsuan Fan, Bin-Shyun Lee, Song-Kun Shyue, Liang-In Lin, Zi-Rui Feng, Ann-Lii Cheng
Publikováno v:
Oncotarget
// Da-Liang Ou 1, 2 , Song-Kun Shyue 3 , Liang-In Lin 4 , Zi-Rui Feng 2, 5 , Jun-Yang Liou 6 , Hsiang-Hsuan Fan 2, 5 , Bin-Shyun Lee 2, 5 , Chiun Hsu 1, 5, 7 , Ann-Lii Cheng 1, 5, 7, 8 1 Graduate Institute of Oncology, College of Medicine, National T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b08ba8dfc5b8b6229195193906a0ba
https://doi.org/10.18632/oncotarget.4446
https://doi.org/10.18632/oncotarget.4446
Autor:
Da-Liang Ou1 dlou@ntu.edu.tw, Bin-Shyun Lee2 demetor.tw@yahoo.com.tw, Liang-In Lin3 lilin@ntu.edu.tw, Jun-Yang Liou4 jliou@nhri.org.tw, Sheng-Chieh Liao5 tonysam6473@yahoo.com.tw, Chiun Hsu6 hsuchiun@gmail.com, Ann-Lii Cheng7 alcheng@ntu.edu.tw
Publikováno v:
Molecular Cancer. 2014, Vol. 13 Issue 1, p1-20. 20p. 5 Graphs.
Publikováno v:
Annals of Oncology. 23:xi16
Background The IGFR signaling pathway plays important roles in carcinogenesis and drug resistance of many cancers, including HCC, but inhibitors targeting the IGF signaling pathway showed limited therapeutic efficacy. This study explored the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae36dca5a577154e437f86119df83337
https://doi.org/10.1016/s0923-7534(20)31955-4
https://doi.org/10.1016/s0923-7534(20)31955-4